Growth Metrics

Akari Therapeutics (AKTX) Change in Acquisitions & Divestments (2016)

Akari Therapeutics recorded quarterly Change in Acquisitions & Divestments of $35.1 million in Q4 2016, up 3342.67% quarter-over-quarter from $1.0 million in Q3 2016.

Akari Therapeutics' Change in Acquisitions & Divestments history runs 1 years deep, the most recent figure standing at $35.1 million for Q4 2016.

  • In Q4 2016, Change in Acquisitions & Divestments changed N/A year-over-year to $35.1 million; the TTM figure through Dec 2017 stood at $36.1 million (changed N/A YoY), while the FY2017 annual figure was $10.0 million, down 72.24% from the prior year.
  • Change in Acquisitions & Divestments came in at $35.1 million for Q4 2016 at Akari Therapeutics, up from $1.0 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $35.1 million in Q4 2016 to a low of $1.0 million in Q3 2016.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Revolution Medicines 32.39 Bn 32.39 Bn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2016 35.08 Mn
Dec 31, 2016 35.08 Mn
Sep 30, 2016 1.02 Mn
Sep 30, 2016 1.02 Mn